Table 2.
Adverse events during hospitalization in patients with prior oral anticoagulation therapy
|
Overall N = 110 |
Atrial fibrillation N = 89 |
Venous thromboembolism a N = 13 |
Mechanical heart valve N = 8 |
P‐value | |
|---|---|---|---|---|---|
| Renal failure, n (%) | 48 (43.6) | 40 (44.9) | 6 (46.2) | 2 (25.0) | .542 |
| Respiratory insufficiency, n (%) | 82 (74.5) | 65 (73.0) | 9 (69.2) | 8 (100) | .220 |
| Upper respiratory tract infection, n (%) | 14 (12.7) | 10 (11.2) | 2 (15.4) | 2 (25.0) | .510 |
| Heart failure, n (%) | 18 (16.4) | 15 (16.9) | 1 (7.7) | 2 (25.0) | .558 |
| Sepsis, n (%) | 31 (28.2) | 26 (29.2) | 5 (38.5) | 0 (0.0) | .145 |
| Systemic inflammatory response syndrome, n (%) | 25 (22.7) | 19 (21.3) | 6 (46.2) | 0 (0.0) | .039 |
| Any relevant bleeding, n (%) b | 8 (7.3) | 5 (5.6) | 1 (7.7) | 2 (25.0) | .129 |
| Primary endpoint (all‐cause mortality), n (%) | 75 (68.2) | 61 (68.5) | 10 (76.9) | 4 (50.0) | .431 |
| Secondary endpoint (all‐cause mortality or any thromboembolic event), n (%) | 76 (69.1) | 61 (68.5) | 10 (76.9) | 5 (62.5) | .760 |
| Pulmonary embolism, n (%) | 2 (1.8) | 1 (1.12) | 0 (0.0) | 1 (12.5) | .084 |
| Stent thrombosis, n (%) | 1 (0.9) | 0 (0.0) | 1 (7.7) | 0 (0.0) |
a
2 patients with other indications for oral anticoagulation have been included in this group (1 with antiphospholipid syndrome and 1 with hypercoagulability)
b
As determined by the attending medical team and classified using the BARC bleeding score as 2, 3, or 5 types. Reported in the clinical history as such.